Ten cases of scabies successfully treated with topical ivermectin
No Thumbnail Available
Authors
Oldham,J.
Sahota,A.
O'Toole,E.
Cunningham,M.
Contact
Check for full-text access
Issue Date
2024
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Scabies is an increasing problem in the UK with a surge in cases reported by dermatologists and the media. It is intensely itchy and caused by the highly contagious mite Sarcoptes scabiei. There are many theories regarding the increased prevalence, including global warming, increased poverty, reduced treatment availability and resistance. The standard treatments in the UK include topical malathion, topical permethrin and oral ivermectin. All have had significant supply issues as reported by the British Association of Dermatologists. There have also been concerns of permethrin resistance. Oral ivermectin is expensive, with four tablets listed at 116.84 in the British National Formulary (BNF). Finally, oral ivermectin is not licensed in children weighing -1 cream Soolantra) to treat 10 patients, with great success. The first was a 14-monthold child who weighed 9.2 kg. She had previously had three courses of permethrin and two courses of malathion with ongoing signs and symptoms of scabies, including burrows. The entire family had been treated every time and the entire family (except this patient) was treated with oral ivermectin during the final treatment before topical ivermectin. The patient was treated top to toe with two applications of topical ivermectin cream 1 week apart, with resolution after one application. Subsequently we have had success using the same protocol to treat a 21-year-old man (with no response to four courses of permethrin) and his 53-year-old mother (with no response to three courses of permethrin). We have also treated a 31-year-old man, a 48-year-old man and his partner (all of whom had not responded to one course of permethrin), and a 68-year-old man and his family who had no previous treatment. We have had no adverse effects and no treatment failures. We report on 10 patients who we treated successfully with topical ivermectin. Topical ivermectin provides an exciting option for treatment and, of note, one tube is listed at 27.43 in the BNF, making it significantly cheaper than the oral alternative.
Description
Citation
Publisher
License
Journal
The British Journal of Dermatology